New drug awaiting FDA approval may reverse bone loss.
出版信息
Mayo Clin Health Lett. 2001 Nov;19(11):4.
PMID:11692627
Abstract
摘要
相似文献
1
New drug awaiting FDA approval may reverse bone loss.
Mayo Clin Health Lett. 2001 Nov;19(11):4.
2
FDA approves AIDS drug.
Am Pharm. 1992 Sep;NS32(9):13-4.
3
TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther. 2002 Apr;2(2):139.
4
Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
Fed Regist. 1998 May 12;63(91):26191-3.
5
FDA approves treatment IND protocol for taxol.
Clin Pharm. 1992 Nov;11(11):912.
6
Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov. 2011 Feb;10(2):86. doi: 10.1038/nrd3363.
7
Charging for investigational drugs under an investigational new drug application. Final rule.
Fed Regist. 2009 Aug 13;74(155):40871-900.
8
The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
Anesth Analg. 2007 Mar;104(3):479-80. doi: 10.1213/01.ane.0000257291.34935.ad.
9
Patient group seeks overhaul of FDA clinical trial system in court.
J Natl Cancer Inst. 2006 Sep 20;98(18):1268-70. doi: 10.1093/jnci/djj401.
10
Expanded access to investigational drugs for treatment use. Final rule.
Fed Regist. 2009 Aug 13;74(155):40900-45.
Zotero 插件